2012
DOI: 10.4081/hr.2012.e10
|View full text |Cite
|
Sign up to set email alerts
|

Romiplostim as Early Treatment of Immune Thrombocytopenia with Severe Immunodeficiency

Abstract: Immunosuppressive agents are the standard therapeutic approach for immune thrombocy-topenia (ITP). Their prolonged use may increase the risk of infectious complications, particularly when the patient is already at higher infectious risk. In this setting, the use of drugs with a mechanism of action alternative to immunosuppression, like thrombopoietin receptor agonists (TRAs), may find particular indication. We report the unique case of a patient with severe immunodeficiency and ITP, who experienced a serious i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 9 publications
0
2
0
Order By: Relevance
“…Romiplostim, a fusion protein analog of TPO, contains two copies of the human immunoglobulin (IgG 1 ) Fc domain, each covalently linked at its C-terminus to a peptide chain containing two c-Mpl-binding peptides [11]. It has been approved in many countries as a treatment for adult patients with chronic ITP [12] and has been shown to increase platelet count (to PLT ≥ 50) in the majority of ITP patients [13][14][15].…”
Section: Pathology and Treatment Of Itpmentioning
confidence: 99%
“…Romiplostim, a fusion protein analog of TPO, contains two copies of the human immunoglobulin (IgG 1 ) Fc domain, each covalently linked at its C-terminus to a peptide chain containing two c-Mpl-binding peptides [11]. It has been approved in many countries as a treatment for adult patients with chronic ITP [12] and has been shown to increase platelet count (to PLT ≥ 50) in the majority of ITP patients [13][14][15].…”
Section: Pathology and Treatment Of Itpmentioning
confidence: 99%
“…Romiplostim has been shown to increase platelet count (to PLT ≥ 50) in the majority of ITP patients (Palandri et al 2012). However, peak platelet count in response to single romiplostim treatment is highly variable from patient to patient (Bussel et al 2006).…”
Section: Pathology and Treatment Of Itpmentioning
confidence: 99%